IGF-1 reduce protein O-GlcNAcylation via AMPK activation in H9C2 cardiomyoblast cultured in high glucose media

Background: Diabetes is a disease characterized by the increase in the serum glucose concentration. Therefore, this glucose excess shunts into the hexosamine biosynthetic pathway producing UDP-GlcNAc, which can be transfer to serine residues and modify the activity of different proteins, including contractile proteins in cardiomyocytes, decreasing their function. Here we show the effect of IGF-1 treatment on this posttranslational modification. Methods: H9c2 cell line were cultured in DMEM media, 10% FBS, at 80% of confluence. Cells were incubated in high-glucose (30 mM) in the presence or absence of 10 µmol/L of IGF-1 (HG and HG+IGF-1). As control groups, we used cells incubated in DMEM with normal glucose (5 mM) in presence or absence of IGF-1 (NG and NG+IGF-1). Compound C (10 µM for 24 h) was used as AMPK inhibitor. After 48 h of incubation proteins were extracted for Western Blot analysis. Results: The effect of IGF-1 on the cells seed with HG media shows a reduction in the O-GlcNAc modification (LG vs HG vs HG+IGF-1; 100±12.5 vs 189±20 vs 132±12). IGF-1 effect on reducing O-GlcNac levels was blocked by Compound C (NG vs HG vs HG+IGF-1; vs 110±7 vs 131±8 vs 132±13). Also, we studied the expression of the two main proteins implicated in this PTM, OGT and OGA, showing no significant differences in protein expression between groups. Conclusion: IGF-1 can be use as potential treatment to restore normal O-GlcNAcylation in diabetic cardiomyopathy

Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Summary Background Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. Methods We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung’s disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. Findings We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung’s disease) from 264 hospitals (89 in high-income countries, 166 in middleincome countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in lowincome countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. Interpretation Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between lowincome, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030

Generating human papillomavirus (HPV) reference databases to maximize genomic mapping

Genomic experiments analyzing human papillomaviruses (HPVs) require a carefully selected list of sequences as a reference database to map millions of reads. The available sources, such as the Papillomavirus Episteme (PaVE), are organized based on variations in the L1 gene rather than the whole HPV sequence. Moreover, the PaVE process uses complex multiple sequence alignments containing hundreds or thousands of sequences. These issues complicate the generation of a reference database for genomics, leading to the generation of per-analysis-defined databases. Here, we propose a de novo strategy considering all HPV sequences reported in the NCBI database to define a subset of highly representative HPV sequences. The strategy is based on oligonucleotide frequency profiling of the whole sequence followed by hierarchical clustering. Using data from HPV capture experiments, we demonstrate that this strategy selects suitable sequences as a reference database to map most mappable reads unambiguously. We provide some recommendations to improve HPV mapping. The generated .fasta files can be accessed at https://github.com/vtrevino/HPV-Ref-Genomes